This study identifies the prognostic factors associated with PFS and OS, gives an overview of the real-world clinical scenario of these patients after 177Lu-PSMA-617 therapy, the patterns of response, alternative subsequent anti-cancer systemic treatments following 177Lu-PSMA-617 therapy, and validate the findings with the short-term reports. The gene discussed is FOLH1; the disease is cancer.